药明康德高位套现子公司，真有这么缺钱？

Core Insights - WuXi AppTec successfully cashed out HKD 24.26 billion through two block trades of its subsidiary WuXi AppTec Holdings, raising concerns about long-term performance despite strong financial results [1] Group 1: Financial Performance - WuXi AppTec Holdings reported a revenue growth of 67.6% year-on-year in its 2024 semi-annual report, with a net profit of CNY 488 million, reflecting a 175.5% increase [1] - The sale of shares resulted in over CNY 2.016 billion in investment income for WuXi AppTec over the past year [2] Group 2: Impact of Share Sale - The transaction is expected to impact the net profit by approximately CNY 720 million in 2024 and CNY 1.297 billion in 2025 [2] - Concerns have been raised regarding the sustainability of high growth rates, especially with significant shareholder sell-offs occurring during a period of strong performance [2] Group 3: Industry Context - WuXi Biologics, another entity in the WuXi ecosystem, also announced asset sales, including a USD 500 million sale of its vaccine plant to Merck [2]